Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies

Sevim Bavbek, Min Jung Lee

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-α inhibitors (etanercept and adalimumab), insulin, and omalizumab.

Original languageEnglish (US)
Pages (from-to)761-771
Number of pages11
JournalImmunology and Allergy Clinics of North America
Issue number4
StatePublished - Nov 2017


  • Adalimumab
  • Etanercept
  • Injection site reactions
  • Insulin
  • MoAbs
  • Omalizumab
  • Systemic hypersensitivity reactions
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies'. Together they form a unique fingerprint.

Cite this